(+)-N-(2-((2-(dimethylamino)ethyl)sulfinyl)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide

ID: ALA4441606

Chembl Id: CHEMBL4441606

PubChem CID: 141509386

Max Phase: Preclinical

Molecular Formula: C27H30N6O3S

Molecular Weight: 518.64

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  C=CC(=O)Nc1cc(Nc2nccc(-c3cn(C)c4ccccc34)n2)c(OC)cc1[S+]([O-])CCN(C)C

Standard InChI:  InChI=1S/C27H30N6O3S/c1-6-26(34)29-22-15-21(24(36-5)16-25(22)37(35)14-13-32(2)3)31-27-28-12-11-20(30-27)19-17-33(4)23-10-8-7-9-18(19)23/h6-12,15-17H,1,13-14H2,2-5H3,(H,29,34)(H,28,30,31)

Standard InChI Key:  QLXFJFOHLZOGEC-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA4441606

   ---

2. Alternative Forms:

   

   ALA4441606

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 518.64

Molecular Weight (Monoisotopic): 518.2100

AlogP: 4.18

#Rotatable Bonds: 10

Polar Surface Area: 107.37

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 11.63

CX Basic pKa: 7.46

CX LogP: 3.91

CX LogD: 3.58

Aromatic Rings: 4

Heavy Atoms: 37

QED Weighted: 0.24

Np Likeness Score: -0.83

References

1. An B, Pan T, Hu J, Pang Y, Huang L, Chan ASC, Li X, Yan J..  (2019)  The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer.,  183  [PMID:31581004] [10.1016/j.ejmech.2019.111709]

2. An B, Pan T, Hu J, Pang Y, Huang L, Chan ASC, Li X, Yan J..  (2019)  The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer.,  183  [PMID:31581004] [10.1016/j.ejmech.2019.111709]

3. An B, Pan T, Hu J, Pang Y, Huang L, Chan ASC, Li X, Yan J..  (2019)  The discovery of a potent and selective third-generation EGFR kinase inhibitor as a therapy for EGFR L858R/T790M double mutant non-small cell lung cancer.,  183  [PMID:31581004] [10.1016/j.ejmech.2019.111709]

4. Li J,An B,Song X,Zhang Q,Chen C,Wei S,Fan R,Li X,Zou Y.  (2021)  Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR inhibitors.,  212  [PMID:33429247] [10.1016/j.ejmech.2020.113019]

Source

Source(1):

• Scientific Literature